{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T04:43:24Z","timestamp":1774327404123,"version":"3.50.1"},"reference-count":99,"publisher":"Elsevier","isbn-type":[{"value":"9780443224201","type":"print"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/bs.pmbts.2024.08.004","type":"book-chapter","created":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T03:16:01Z","timestamp":1725074161000},"page":"47-93","source":"Crossref","is-referenced-by-count":3,"title":["Recent development in CRISPR-Cas systems for cardiac disease"],"prefix":"10.1016","author":[{"given":"Ingita Dey","family":"Munshi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mansi","family":"Acharya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sridip","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7690-5517","authenticated-orcid":false,"given":"Indra","family":"Mani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/bs.pmbts.2024.08.004_bib1","first-page":"353","article-title":"Mechanism and applications of CRISPR\/Cas-9-mediated genome editing","volume":"15","author":"Asmamaw","year":"2021","journal-title":"Biologics"},{"issue":"20","key":"10.1016\/bs.pmbts.2024.08.004_bib2","doi-asserted-by":"crossref","first-page":"10985","DOI":"10.3390\/ijms222010985","article-title":"Recent advances in CRISPR\/Cas9-based genome editing tools for cardiac diseases","volume":"22","author":"Schreurs","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/bs.pmbts.2024.08.004_bib3","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1080\/13543784.2020.1757070","article-title":"Gene-based therapy in lipid management: the winding road from promise to practice","volume":"29","author":"Tromp","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/bs.pmbts.2024.08.004_bib4","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/bs.pmbts.2021.01.021","article-title":"Genome editing in cardiovascular diseases","volume":"181","author":"Mani","year":"2021","journal-title":"Prog Mol Biol Transl Sci"},{"key":"10.1016\/bs.pmbts.2024.08.004_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.662583","article-title":"Zebrafish heart failure models","volume":"9","author":"Narumanchi","year":"2021","journal-title":"Front Cell Dev Biol"},{"issue":"10","key":"10.1016\/bs.pmbts.2024.08.004_bib6","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1161\/ATVBAHA.123.319189","article-title":"Conditional, tissue-specific CRISPR\/Cas9 vector system in zebrafish reveals the role of Nrp1b in heart regeneration","volume":"43","author":"Singh Angom","year":"2023","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"10.1016\/bs.pmbts.2024.08.004_bib7","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1093\/cvr\/cvz250","article-title":"CRISPR\/Cas9 gene-editing strategies in cardiovascular cells","volume":"116","author":"Vermersch","year":"2020","journal-title":"Cardiovasc Res"},{"key":"10.1016\/bs.pmbts.2024.08.004_bib8","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.jconrel.2022.02.005","article-title":"Current approaches in CRISPR-Cas9 mediated gene editing for biomedical and therapeutic applications","volume":"343","author":"Bhattacharjee","year":"2022","journal-title":"J Control Rel"},{"issue":"17","key":"10.1016\/bs.pmbts.2024.08.004_bib9","doi-asserted-by":"crossref","first-page":"6240","DOI":"10.3390\/ijms21176240","article-title":"CRISPR-Cas9 DNA base-editing and prime-editing","volume":"21","author":"Kantor","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"7320","key":"10.1016\/bs.pmbts.2024.08.004_bib10","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature09523","article-title":"The CRISPR\/Cas bacterial immune system cleaves bacteriophage and plasmid DNA","volume":"468","author":"Garneau","year":"2010","journal-title":"Nature"},{"issue":"5819","key":"10.1016\/bs.pmbts.2024.08.004_bib11","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1126\/science.1138140","article-title":"CRISPR provides acquired resistance against viruses in prokaryotes","volume":"315","author":"Barrangou","year":"2007","journal-title":"Science"},{"issue":"2","key":"10.1016\/bs.pmbts.2024.08.004_bib12","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.tibtech.2017.07.007","article-title":"Advances in industrial biotechnology using CRISPR-Cas systems","volume":"36","author":"Donohoue","year":"2018","journal-title":"Trends Biotechnol"},{"issue":"12","key":"10.1016\/bs.pmbts.2024.08.004_bib13","doi-asserted-by":"crossref","first-page":"5429","DOI":"10.1128\/jb.169.12.5429-5433.1987","article-title":"Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product","volume":"169","author":"Ishino","year":"1987","journal-title":"J Bacteriol"},{"issue":"Pt 8","key":"10.1016\/bs.pmbts.2024.08.004_bib14","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1099\/mic.0.28048-0","article-title":"Clustered regularly interspaced short palindrome repeats (CRISPRs) have spacers of extrachromosomal origin","volume":"151","author":"Bolotin","year":"2005","journal-title":"Microbiology (Read)"},{"key":"10.1016\/bs.pmbts.2024.08.004_bib15","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/nature10886","article-title":"RNA-guided genetic silencing systems in bacteria and archaea","volume":"482","author":"Wiedenheft","year":"2012","journal-title":"Nature"},{"issue":"2","key":"10.1016\/bs.pmbts.2024.08.004_bib16","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/j.1365-2958.2010.07465.x","article-title":"A dual function of the CRISPR-Cas system in bacterial antivirus immunity and DNA repair","volume":"79","author":"Babu","year":"2011","journal-title":"Mol Microbiol"},{"issue":"6","key":"10.1016\/bs.pmbts.2024.08.004_bib17","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.str.2009.03.019","article-title":"Structural basis for DNase activity of a conserved protein implicated in CRISPR-mediated genome defense","volume":"17","author":"Wiedenheft","year":"2009","journal-title":"Structure"},{"issue":"5891","key":"10.1016\/bs.pmbts.2024.08.004_bib18","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1126\/science.1159689","article-title":"Small CRISPR RNAs guide antiviral defense in prokaryotes","volume":"321","author":"Brouns","year":"2008","journal-title":"Science"},{"issue":"5997","key":"10.1016\/bs.pmbts.2024.08.004_bib19","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1126\/science.1192272","article-title":"Sequence- and structure-specific RNA processing by a CRISPR endonuclease","volume":"329","author":"Haurwitz","year":"2010","journal-title":"Science"},{"issue":"7340","key":"10.1016\/bs.pmbts.2024.08.004_bib20","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/nature09886","article-title":"CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III","volume":"471","author":"Deltcheva","year":"2011","journal-title":"Nature"},{"issue":"7280","key":"10.1016\/bs.pmbts.2024.08.004_bib21","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature08703","article-title":"Self versus non-self discrimination during CRISPR RNA-directed immunity","volume":"463","author":"Marraffini","year":"2010","journal-title":"Nature"},{"issue":"25","key":"10.1016\/bs.pmbts.2024.08.004_bib22","doi-asserted-by":"crossref","first-page":"10098","DOI":"10.1073\/pnas.1104144108","article-title":"Interference by clustered regularly interspaced short palindromic repeat (CRISPR) RNA is governed by a seed sequence","volume":"108","author":"Semenova","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"25","key":"10.1016\/bs.pmbts.2024.08.004_bib23","doi-asserted-by":"crossref","first-page":"10092","DOI":"10.1073\/pnas.1102716108","article-title":"RNA-guided complex from a bacterial immune system enhances target recognition through seed sequence interactions","volume":"108","author":"Wiedenheft","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/bs.pmbts.2024.08.004_bib24","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.molcel.2008.12.012","article-title":"Enhancement of the seed-target recognition step in RNA silencing by a PIWI\/MID domain protein","volume":"33","author":"Parker","year":"2009","journal-title":"Mol Cell"},{"issue":"36","key":"10.1016\/bs.pmbts.2024.08.004_bib25","doi-asserted-by":"crossref","first-page":"31896","DOI":"10.1074\/jbc.M111.270017","article-title":"Structural and biochemical analysis of nuclease domain of clustered regularly interspaced short palindromic repeat (CRISPR)-associated protein 3 (Cas3)","volume":"286","author":"Mulepati","year":"2011","journal-title":"J Biol Chem"},{"issue":"7","key":"10.1016\/bs.pmbts.2024.08.004_bib26","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1038\/emboj.2011.41","article-title":"Cas3 is a single-stranded DNA nuclease and ATP-dependent helicase in the CRISPR\/Cas immune system","volume":"30","author":"Sinkunas","year":"2011","journal-title":"EMBO J"},{"issue":"5","key":"10.1016\/bs.pmbts.2024.08.004_bib27","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.cell.2009.07.040","article-title":"RNA-guided RNA cleavage by a CRISPR RNA-Cas protein complex","volume":"139","author":"Hale","year":"2009","journal-title":"Cell"},{"issue":"11","key":"10.1016\/bs.pmbts.2024.08.004_bib28","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/nrmicro3569","article-title":"An updated evolutionary classification of CRISPR-Cas systems","volume":"13","author":"Makarova","year":"2015","journal-title":"Nat Rev Microbiol"},{"issue":"3","key":"10.1016\/bs.pmbts.2024.08.004_bib29","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrmicro.2016.184","article-title":"Diversity and evolution of class 2 CRISPR-Cas systems","volume":"15","author":"Shmakov","year":"2017","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/bs.pmbts.2024.08.004_bib30","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1126\/science.1225829","article-title":"A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity","volume":"337","author":"Jinek","year":"2012","journal-title":"Science"},{"issue":"Pt 3","key":"10.1016\/bs.pmbts.2024.08.004_bib31","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1099\/mic.0.023960-0","article-title":"Short motif sequences determine the targets of the prokaryotic CRISPR defence system","volume":"155","author":"Mojica","year":"2009","journal-title":"Microbiology (Read)"},{"issue":"2","key":"10.1016\/bs.pmbts.2024.08.004_bib32","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.tcm.2019.03.005","article-title":"Harnessing CRISPR\/Cas9 technology in cardiovascular disease","volume":"30","author":"Rezaei","year":"2020","journal-title":"Trends Cardiovasc Med"},{"issue":"12","key":"10.1016\/bs.pmbts.2024.08.004_bib33","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCRESAHA.122.320496","article-title":"CRISPR modeling and correction of cardiovascular disease","volume":"130","author":"Liu","year":"2022","journal-title":"Circ Res"},{"issue":"1","key":"10.1016\/bs.pmbts.2024.08.004_bib34","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/cvr\/cvac048","article-title":"CRISPR and cardiovascular diseases","volume":"119","author":"Musunuru","year":"2023","journal-title":"Cardiovasc Res"},{"key":"10.1016\/bs.pmbts.2024.08.004_bib35","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41392-023-01526-0","article-title":"CRISPRing the hypertrophic cardiomyopathy: correcting one pathogenic variant at a time","volume":"8","author":"Afzal","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/bs.pmbts.2024.08.004_bib36","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/s41591-022-02190-7","article-title":"Efficient in vivo gene editing prevents hypertrophic cardiomyopathy in mice","volume":"29","author":"Reichart","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/bs.pmbts.2024.08.004_bib37","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/s41591-022-02176-5","article-title":"Base editing correction of hypertrophic cardiomyopathy in human cardiomyocytes humanized mice","volume":"29","author":"Chai","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/bs.pmbts.2024.08.004_bib38","unstructured":"Mahmaljy H, Yelamanchili VS, Singhal M. Dilated cardiomyopathy. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 April 7. 2024 January. PMID: 28722940."},{"issue":"3","key":"10.1016\/bs.pmbts.2024.08.004_bib39","article-title":"Clustered regularly interspaced short palindromic repeats (CRISPR) in cardiovascular disease: a comprehensive clinical review on dilated cardiomyopathy","volume":"15","author":"Ganipineni","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/bs.pmbts.2024.08.004_bib40","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1093\/cvr\/cvac021","article-title":"Gene editing reverses arrhythmia susceptibility in humanized PLN-R14del mice: modelling a European cardiomyopathy with global impact","volume":"118","author":"Dave","year":"2022","journal-title":"Cardiovasc Res"},{"key":"10.1016\/bs.pmbts.2024.08.004_bib41","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.124297","article-title":"AAV CRISPR editing rescues cardiac and muscle function for 18 months in dystrophic mice","volume":"3","author":"Hakim","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/bs.pmbts.2024.08.004_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.scr.2021.102544","article-title":"Modeling of dilated cardiomyopathy by establishment of isogenic human iPSC lines carrying phospholamban C25T (R9C) mutation (UPITTi002-A-1) using CRISPR\/Cas9 editing","volume":"56","author":"Barndt","year":"2021","journal-title":"Stem Cell Res"},{"key":"10.1016\/bs.pmbts.2024.08.004_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.scr.2020.102077","article-title":"CRISPR\/Cas9 mediated establishment of a human CSRP3 compound heterozygous knockout hESC line to model cardiomyopathy and heart failure","volume":"49","author":"Sun","year":"2020","journal-title":"Stem Cell Res"},{"key":"10.1016\/bs.pmbts.2024.08.004_bib44","doi-asserted-by":"crossref","first-page":"dmm032201","DOI":"10.1242\/dmm.032201","article-title":"A novel rabbit model of Duchenne muscular dystrophy generated by CRISPR\/Cas9","volume":"11","author":"Sui","year":"2018","journal-title":"Dis Model Mech"},{"issue":"23","key":"10.1016\/bs.pmbts.2024.08.004_bib45","article-title":"Gene editing to prevent ventricular arrhythmias associated with cardiomyocyte cell therapy","volume":"S1934-5909","author":"Marchiano","year":"2023","journal-title":"Stem Cell"},{"issue":"8","key":"10.1016\/bs.pmbts.2024.08.004_bib46","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.3390\/cells12101363","article-title":"Genome editing and cardiac arrhythmias","volume":"12","author":"Moore","year":"2023","journal-title":"Cells"},{"key":"10.1016\/bs.pmbts.2024.08.004_bib47","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1161\/CIRCRESAHA.118.313876","article-title":"Getting into the rhythm with CRISPR","volume":"122","author":"Vanden Driessche","year":"2018","journal-title":"Circ Res"},{"issue":"3","key":"10.1016\/bs.pmbts.2024.08.004_bib48","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/MOL.0000000000000591","article-title":"CRISPR: a promising tool for lipid physiology and therapeutics","volume":"30","author":"Furgurson","year":"2019","journal-title":"Curr Opin Lipidol"},{"issue":"12","key":"10.1016\/bs.pmbts.2024.08.004_bib49","doi-asserted-by":"crossref","first-page":"857","DOI":"10.3390\/metabo11120857","article-title":"CRISPR gene editing in lipid disorders and atherosclerosis: mechanisms and opportunities","volume":"11","author":"Walker","year":"2021","journal-title":"Metabolites"},{"issue":"12","key":"10.1016\/bs.pmbts.2024.08.004_bib50","first-page":"1825","article-title":"Development of new genome editing tools for the treatment of hyperlipidemia","volume":"12","author":"Preta","year":"2023","journal-title":"Cells"},{"key":"10.1016\/bs.pmbts.2024.08.004_bib51","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.atherosclerosis.2023.01.010","article-title":"Gene editing for dyslipidemias: new tools to \u201ccut\u201d lipids","volume":"368","author":"Stankov","year":"2023","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/bs.pmbts.2024.08.004_bib52","first-page":"1043","article-title":"PCSK9 as a target for development of a new generation of hypolipidemic drugs","volume":"27","author":"Kumzich","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/bs.pmbts.2024.08.004_bib53","article-title":"Efficacy and safety of an investigational single-course CRISPR base-editing therapy targeting PCSK9 in nonhuman primate and mouse models","author":"Lee","year":"2023","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/bs.pmbts.2024.08.004_bib54","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.jacbts.2019.05.008","article-title":"Angiopoietin-Like 3: From discovery to therapeutic gene editing","volume":"4","author":"Wang","year":"2019","journal-title":"JACC Basic Transl Sci"},{"issue":"11","key":"10.1016\/bs.pmbts.2024.08.004_bib55","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s11883-022-01071-1","article-title":"ANGPTL3 as a drug target in hyperlipidemia and atherosclerosis","volume":"24","author":"Mohamed","year":"2022","journal-title":"Curr Atheroscler Rep"},{"issue":"9","key":"10.1016\/bs.pmbts.2024.08.004_bib56","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1161\/CIRCULATIONAHA.117.031335","article-title":"Reduced blood lipid levels with in vivo CRISPR-Cas9 base editing of ANGPTL3","volume":"137","author":"Chadwick","year":"2018","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/bs.pmbts.2024.08.004_bib57","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13578-023-01036-0","article-title":"Liver-specific in vivo base editing of Angptl3 via AAV delivery efficiently lowers blood lipid levels in mice","volume":"13","author":"Zuo","year":"2023","journal-title":"Cell Biosci"},{"issue":"1","key":"10.1016\/bs.pmbts.2024.08.004_bib58","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11883-022-01076-w","article-title":"How ANGPTL3 inhibition will help our clinical practice?","volume":"25","author":"Bini","year":"2023","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/bs.pmbts.2024.08.004_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2024.100500","article-title":"ANGPTL3 deficiency impairs lipoprotein production and produces adaptive changes in hepatic lipid metabolism","volume":"65","author":"Burks","year":"2024","journal-title":"J Lipid Res"},{"issue":"12","key":"10.1016\/bs.pmbts.2024.08.004_bib60","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0168486","article-title":"Phospholamban ablation using CRISPR\/Cas9 system improves mortality in a murine heart failure model","volume":"11","author":"Kaneko","year":"2016","journal-title":"PLoS One"},{"issue":"618","key":"10.1016\/bs.pmbts.2024.08.004_bib61","doi-asserted-by":"crossref","first-page":"eabd3079","DOI":"10.1126\/scitranslmed.abd3079","article-title":"Truncated titin proteins and titin haploinsufficiency are targets for functional recovery in human cardiomyopathy due to TTN mutations","volume":"13","author":"Fomin","year":"2021","journal-title":"Sci Transl Med"},{"issue":"4","key":"10.1016\/bs.pmbts.2024.08.004_bib62","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.yjmcc.2007.07.045","article-title":"Factors controlling cardiac myosin-isoform shift during hypertrophy and heart failure","volume":"43","author":"Gupta","year":"2007","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/bs.pmbts.2024.08.004_bib63","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1471-2350-13-17","article-title":"High resolution melting: improvements in the genetic diagnosis of hypertrophic cardiomyopathy in a Portuguese cohort","volume":"13","author":"Santos","year":"2012","journal-title":"BMC Med Genet"},{"issue":"1","key":"10.1016\/bs.pmbts.2024.08.004_bib64","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1161\/CIRCULATIONAHA.104.507699","article-title":"Alpha-myosin heavy chain: a sarcomeric gene associated with dilated and hypertrophic phenotypes of cardiomyopathy","volume":"112","author":"Carniel","year":"2005","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/bs.pmbts.2024.08.004_bib65","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1161\/CIRCGENETICS.109.912345","article-title":"Coding sequence rare variants identified in MYBPC3, MYH6, TPM1, TNNC1, and TNNI3 from 312 patients with familial or idiopathic dilated cardiomyopathy","volume":"3","author":"Hershberger","year":"2010","journal-title":"Circ Cardiovasc Genet"},{"issue":"12","key":"10.1016\/bs.pmbts.2024.08.004_bib66","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0028872","article-title":"Cardiac alpha-myosin (MYH6) is the predominant sarcomeric disease gene for familial atrial septal defects","volume":"6","author":"Posch","year":"2011","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/bs.pmbts.2024.08.004_bib67","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1161\/CIRCRESAHA.116.310370","article-title":"Postnatal cardiac gene editing using CRISPR\/Cas9 with AAV9-mediated delivery of short guide RNAs results in mosaic gene disruption","volume":"121","author":"Johansen","year":"2017","journal-title":"Circ Res"},{"issue":"8","key":"10.1016\/bs.pmbts.2024.08.004_bib68","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1172\/JCI118992","article-title":"Ablation of the murine alpha myosin heavy chain gene leads to dosage effects and functional deficits in the heart","volume":"98","author":"Jones","year":"1996","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/bs.pmbts.2024.08.004_bib69","first-page":"212","article-title":"A mouse model for adult cardiac-specific gene deletion with CRISPR\/Cas9","volume":"112","author":"Carroll","year":"2015","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/bs.pmbts.2024.08.004_bib70","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/bs.pmbts.2021.01.011","article-title":"CRISPR-Cas systems for genome editing of mammalian cells","volume":"181","author":"Mani","year":"2021","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"7785","key":"10.1016\/bs.pmbts.2024.08.004_bib71","first-page":"149","article-title":"Prime editing: precision genome editing by reverse transcription","volume":"576","author":"Chen","year":"2020","journal-title":"Nature"},{"issue":"1","key":"10.1016\/bs.pmbts.2024.08.004_bib72","article-title":"Gene editing therapy for cardiovascular diseases","volume":"5","author":"Wu","year":"2024","journal-title":"MedComm"},{"issue":"7","key":"10.1016\/bs.pmbts.2024.08.004_bib73","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/s41587-020-0561-9","article-title":"Genome editing with CRISPR\u2013Cas nucleases, base editors, transposases and prime editors","volume":"38","author":"Anzalone","year":"2020","journal-title":"Nat Biotechnol"},{"issue":"11","key":"10.1016\/bs.pmbts.2024.08.004_bib74","doi-asserted-by":"crossref","first-page":"6072","DOI":"10.3390\/ijms22116072","article-title":"CRISPR\/Cas9: principle, applications, and delivery through extracellular vesicles","volume":"22","author":"Horodecka","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/bs.pmbts.2024.08.004_bib75","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.stem.2019.02.005","article-title":"Targeted disruption of HLA genes via CRISPR-Cas9 generates iPSCs with enhanced immune compatibility","volume":"24","author":"Xu","year":"2019","journal-title":"Cell Stem Cell"},{"issue":"6","key":"10.1016\/bs.pmbts.2024.08.004_bib76","doi-asserted-by":"crossref","first-page":"839","DOI":"10.3390\/biom10060839","article-title":"Recent advances in CRISPR\/Cas9 delivery strategies","volume":"10","author":"Yip","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/bs.pmbts.2024.08.004_bib77","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jconrel.2022.01.013","article-title":"Delivery of CRISPR-Cas tools for in vivo genome editing therapy: trends and challenges","volume":"342","author":"Taha","year":"2022","journal-title":"J Control Rel"},{"issue":"10","key":"10.1016\/bs.pmbts.2024.08.004_bib78","doi-asserted-by":"crossref","first-page":"24751","DOI":"10.3390\/ijms161024751","article-title":"Minimizing off-target mutagenesis risks caused by programmable nucleases","volume":"16","author":"Ishida","year":"2015","journal-title":"Int J Mol Sci"},{"key":"10.1016\/bs.pmbts.2024.08.004_bib79","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jbiotec.2015.04.024","article-title":"Rapid and highly efficient mammalian cell engineering via Cas9 protein transfection","volume":"208","author":"Liang","year":"2015","journal-title":"J Biotechnol"},{"issue":"5","key":"10.1016\/bs.pmbts.2024.08.004_bib80","doi-asserted-by":"crossref","DOI":"10.1038\/s41551-017-0066","article-title":"Engineering CRISPR-Cpf1 crRNAs and mRNAs to maximize genome editing efficiency","volume":"1","author":"Li","year":"2017","journal-title":"Nat Biomed Eng"},{"issue":"4","key":"10.1016\/bs.pmbts.2024.08.004_bib81","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.stemcr.2021.02.013","article-title":"Efficient ssODN-mediated targeting by avoiding cellular inhibitory RNAs through precomplexed CRISPR-Cas9\/sgRNA ribonucleoprotein","volume":"16","author":"Kagita","year":"2021","journal-title":"Stem Cell Rep"},{"issue":"13","key":"10.1016\/bs.pmbts.2024.08.004_bib82","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1182\/blood-2011-09-382317","article-title":"Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer","volume":"119","author":"Buchlis","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/bs.pmbts.2024.08.004_bib83","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1146\/annurev-virology-031413-085355","article-title":"AAV-mediated gene therapy for research and therapeutic purposes","volume":"1","author":"Samulski","year":"2014","journal-title":"Annu Rev Virol"},{"issue":"7546","key":"10.1016\/bs.pmbts.2024.08.004_bib84","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/nature14299","article-title":"In vivo genome editing using Staphylococcus aureus Cas9","volume":"520","author":"Ran","year":"2015","journal-title":"Nature"},{"issue":"13","key":"10.1016\/bs.pmbts.2024.08.004_bib85","doi-asserted-by":"crossref","first-page":"6450","DOI":"10.1093\/nar\/gkv601","article-title":"Development of an intein-mediated split\u2013Cas9 system for gene therapy","volume":"43","author":"Truong","year":"2015","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"10.1016\/bs.pmbts.2024.08.004_bib86","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/(SICI)1096-9071(199911)59:3<406::AID-JMV22>3.0.CO;2-N","article-title":"Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV)","volume":"59","author":"Erles","year":"1999","journal-title":"J Med Virol"},{"issue":"6","key":"10.1016\/bs.pmbts.2024.08.004_bib87","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.ymthe.2020.04.017","article-title":"AAV-CRISPR gene editing is negated by pre-existing immunity to Cas9","volume":"28","author":"Li","year":"2020","journal-title":"Mol Ther"},{"issue":"6","key":"10.1016\/bs.pmbts.2024.08.004_bib88","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/gt.2012.20","article-title":"Directed evolution of novel adeno- associated viruses for therapeutic gene delivery","volume":"19","author":"Bartel","year":"2012","journal-title":"Gene Ther"},{"issue":"1","key":"10.1016\/bs.pmbts.2024.08.004_bib89","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1089\/hum.2013.2527","article-title":"Adenovirus: the first effective in vivo gene delivery vector","volume":"25","author":"Crystal","year":"2014","journal-title":"Hum Gene Ther"},{"issue":"2","key":"10.1016\/bs.pmbts.2024.08.004_bib90","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1476-5381.2009.00057.x","article-title":"Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics","volume":"157","author":"Heitz","year":"2009","journal-title":"Br J Pharmacol"},{"issue":"6481","key":"10.1016\/bs.pmbts.2024.08.004_bib91","doi-asserted-by":"crossref","DOI":"10.1126\/science.aba7365","article-title":"CRISPR-engineered T cells in patients with refractory cancer","volume":"367","author":"Stadtmauer","year":"2020","journal-title":"Science"},{"key":"10.1016\/bs.pmbts.2024.08.004_bib92","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1817426","article-title":"CRISPR-edited stem cells in a patient with HIV and acute lymphocytic leukemia","author":"Xu","year":"2019","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/bs.pmbts.2024.08.004_bib93","doi-asserted-by":"crossref","DOI":"10.1002\/jgm.3107","article-title":"Delivery of CRISPR\/Cas9 for therapeutic genome editing","volume":"21","author":"Xu","year":"2019","journal-title":"J Gene Med"},{"key":"10.1016\/bs.pmbts.2024.08.004_bib94","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.addr.2013.11.008","article-title":"Understanding ultrasound induced sonoporation: definitions and underlying mechanisms","volume":"72","author":"Lentacker","year":"2014","journal-title":"Adv Drug Deliv Rev"},{"issue":"5","key":"10.1016\/bs.pmbts.2024.08.004_bib95","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1177\/0300060519840890","article-title":"Ultrasound microbubble-mediated CRISPR\/Cas9 knockout of C-erbB-2 in HEC-1A cells","volume":"47","author":"Cai","year":"2019","journal-title":"J Int Med Res"},{"key":"10.1016\/bs.pmbts.2024.08.004_bib96","doi-asserted-by":"crossref","unstructured":"RyuJ-Y, et al., Ultrasound-activated particles as CRISPR\/Cas9 delivery system for androgenic alopecia therapy. Biomaterials 232;2020:119736. https:\/\/doi.org\/10.1016\/j.biomaterials.2019.119736.","DOI":"10.1016\/j.biomaterials.2019.119736"},{"issue":"1","key":"10.1016\/bs.pmbts.2024.08.004_bib97","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1080\/10717544.2018.1474964","article-title":"Delivering CRISPR: a review of the challenges and approaches","volume":"25","author":"Lino","year":"2018","journal-title":"Drug Deliv"},{"key":"10.1016\/bs.pmbts.2024.08.004_bib98","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jconrel.2021.02.026","article-title":"Co-encapsulation of Cas9 mRNA and guide RNA in polyplex micelles enables genome editing in mouse brain","volume":"332","author":"Abbasi","year":"2021","journal-title":"J Control Rel"},{"issue":"6","key":"10.1016\/bs.pmbts.2024.08.004_bib99","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Progress in Molecular Biology and Translational Science","CRISPR-Cas-Based Genome Editing for Treating Human Diseases-Part B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187711732400173X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187711732400173X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T14:38:35Z","timestamp":1736951915000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S187711732400173X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9780443224201"],"references-count":99,"URL":"https:\/\/doi.org\/10.1016\/bs.pmbts.2024.08.004","relation":{},"ISSN":["1877-1173"],"issn-type":[{"value":"1877-1173","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]}}}